Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Heart Drug · 2001
DOI: 10.1159/000048945 ↗Kurz gefasst
Fachartikel in der Zeitschrift Heart Drug, 2001. Verfasst von M.S. Spence und 4 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.
Abstract (Originalsprache)
Platelet activation following the erosion or rupture of an atherosclerotic plaque is central to the development of acute coronary syndromes (ACS). Inhibition of the final common pathway of platelet aggregation using glycoprotein (GP) IIb/IIIa inhibitors has been evaluated in large-scale trials of patients with ACS. There is now consistent evidence across several trials using different parenteral GP IIb/IIIa inhibitors of improved outcomes for ACS patients treated with these agents both as primary treatment and as an adjunct to coronary intervention. The benefits particularly relate to high-risk patients. In contrast oral GP IIb/IIIa inhibitors have not been shown to improve outcomes in ACS patients.
Zitieren
APA
Spence, M., Mathew, T., Manoharan, G., Riddell, J., & Adgey, A. (2001). Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. Heart Drug. https://doi.org/10.1159/000048945
Vancouver
Spence M, Mathew T, Manoharan G, Riddell J, Adgey A. Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes. Heart Drug. 2001. doi:10.1159/000048945
BibTeX
@article{Spence2001,
author = {Spence, M.S. and Mathew, T.P. and Manoharan, G. and Riddell, J.W. and Adgey, A.A.J.},
title = {Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes},
journal = {Heart Drug},
year = {2001},
doi = {10.1159/000048945}
}
EUVIMED